Tivic Health Systems, Inc. (TIVC) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to TIVIC Health System's second quarter 2025 financial results and operational update conference call. This call has been prerecorded. This call is being webcast, and the replay will be available on the IR section of the company's website for three months. Before we begin, let me remind you that during today's call, management will make various forward-looking statements. Investors are cautioned that these forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated in our forward-looking statements. Please read the Safe Harbor Statement contained in the press release that TIVIC Health issued today, as well as the risk factors contained in TIVIC Health's filings with the SEC, including its annual report on Form 10-K of the year end December 31, 2024, and the Form 10-Q to be filed with the SEC today, as well as other companies' SEC filings. On today's call, we have TIVIC Health Chief Executive Officer Jennifer Ernst and Chief Financial Officer Lisa Wolf. Now, Let me turn the call over to Jennifer Ernst. Thank you and welcome to those of you who are joining us today. Before we cover the financial portion of the earnings call, I want to lay the groundwork for those who may have just begun to follow Tyvek. Over the course of the last six months, we have reshaped the company by expanding Tyvek into the biopharmaceutical sector. We've also been advancing ongoing work with our next generation of vagus nerve stimulation devices. This combination of assets makes TIVIC unique in having the ability to treat disease by addressing both the body's biochemical and bioelectronic systems that regulate immune responses. We believe we now have quite a...